A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer

Cancer

Volumn 117, Issue 10, 2011, Pages 2178-2185

  Han, Ji Youn ^a   Lim, Kun Young ^a   Yu, Sun Young ^a   Yun, Tak ^a   Kim, Heung Tae ^a   Lee, Jin Soo ^a  

^a National Cancer Center   (South Korea)

Author keywords

irinotecan; pack years; simvastatin; small cell lung carcinoma

Indexed keywords

CISPLATIN; IRINOTECAN; SIMVASTATIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HAZARD RATIO; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SMOKING; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIPIDS; LIPOPROTEINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SIMVASTATIN; SMALL CELL LUNG CARCINOMA; SMOKING;

EID: 79955486467     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25790     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96. (Pubitemid 351521864)
2. Simon GR, Turrisi A,. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines. Chest. 2007; 132: 324S-339S. (Pubitemid 47505212)
3. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002; 346: 85-91. (Pubitemid 34438898)
4. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006; 24: 2038-2043. (Pubitemid 46622112)
5. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009; 27: 2530-2535.
6. Demierre MF, Higgins PD, Gruber SB, et al. Statins and cancer prevention. Nat Rev Cancer. 2005; 5: 930-942. (Pubitemid 41766782)
7. Chan KK, Oza AM, Siu LL,. The statins as anticancer agents. Clin Cancer Res. 2003; 9: 10-19. (Pubitemid 36109711)
8. Hindler K, Cleeland CS, Rivera E, et al. The role of statins in cancer therapy. Oncologist. 2006; 11: 306-315.
9. Khurana V, Bejjanki HR, Caldito G, et al. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest. 2007; 131: 1282-1288. (Pubitemid 46762329)
10. Farwell WR, Scranton RE, Lawler EV, et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst. 2008; 100: 134-139. (Pubitemid 351480564)
11. Roudier E, Mistafa O, Stenius U,. Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Mol Cancer Ther. 2006; 5: 2706-2715. (Pubitemid 44848997)
12. Khanzada UK, Pardo OE, Meier C, et al. Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signaling. Oncogene. 2006; 25: 877-887. (Pubitemid 43237706)
13. Park IH, Kim JY, Choi JY, et al. Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity [published online ahead of print May 13, 2010]. Invest New Drugs. 2010.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
15. Therneau TAE,. An Introduction to Recursive Partitioning Using the RPART Routine. Technical Report. Rochester, NY: Section of Biostatistics, Mayo Clinic; 1997.
16. Takahashi H, Ogata H, Nishigaki R, et al. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell. 2010; 17: 89-97.
17. Khuder SA,. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer. 2001; 31: 139-148. (Pubitemid 32107010)
18. Dasgupta P, Rizwani W, Pillai S, et al. Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer. 2009; 124: 36-45.
19. Tammemagi CM, Neslund-Dudas C, Simoff M, et al. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest. 2004; 125: 27-37. (Pubitemid 38114560)
20. Ou SH, Ziogas A, Zell JA,. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol. 2009; 4: 37-43.
21. Duarte RL, Luiz RR, Paschoal ME,. The cigarette burden (measured by the number of pack-years smoked) negatively impacts the response rate to platinum-based chemotherapy in lung cancer patients. Lung Cancer. 2008; 61: 244-254.
22. van Gestel YR, Hoeks SE, Sin DD, et al. COPD and cancer mortality: the influence of statins. Thorax. 2009; 64: 963-967.
23. Hanbali AS, Urbaez DE, Wang D, et al. The use of statins and the effect on survival in patients with small cell lung cancer [abstract]. J Clin Oncol. 2006; 24: 18S. Abstract 17121.
24. Wojcik C, Bury M, Stoklosa T, et al. Lovastatin and simvastatin are modulators of the proteasome. Int J Biochem Cell Biol. 2000; 32: 957-965.
25. Efuet ET, Keyomarsi K,. Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome. Cancer Res. 2006; 66: 1040-1051. (Pubitemid 43165972)
26. Karin M, Greten FR,. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005; 5: 749-759. (Pubitemid 41400849)
27. Pikarsky E, Porat RM, Stein I, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004; 431: 461-466. (Pubitemid 39329586)
28. Tsurutani J, Castillo SS, Brognard J, et al. Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis. 2005; 26: 1182-1195. (Pubitemid 41417895)
29. Tang X, Liu D, Shishodia S, et al. Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer. 2006; 107: 2637-2646. (Pubitemid 44845619)